RNA
Atrium Therapeutics, Inc.NASDAQHealthcare$13.44-0.22%ClosedMarket Cap: $208.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.11
P/S
11.20
EV/EBITDA
0.76
DCF Value
$-21.08
FCF Yield
-20.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-412.6%
Net Margin
-411.9%
ROE
-37.0%
ROA
-27.5%
ROIC
-31.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $859.0K | 100.0% | $-48.0M | $-48.1M | $0.00 | — |
| FY 2025 | $18.6M | 100.0% | $-76.8M | $-76.7M | $-4.48 | — |
| Q3 2025 | $12.5M | 100.0% | $-188.8M | $-174.4M | $-1.27 | — |
| Q2 2025 | $3.8M | -3490.5% | $-171.1M | $-157.3M | $-1.21 | — |
| Q1 2025 | $1.6M | 100.0% | $-131.5M | $-115.8M | $-0.90 | — |
| Q4 2024 | $3.0M | 100.0% | $-121.0M | $-102.3M | $-0.80 | — |
| FY 2024 | $10.9M | 100.0% | $-378.9M | $-322.3M | $-2.89 | — |
| Q3 2024 | $2.3M | 100.0% | $-98.1M | $-80.4M | $-0.65 | — |
| Q2 2024 | $2.0M | 66.4% | $-82.6M | $-70.8M | $-0.66 | — |
| Q1 2024 | $3.5M | 81.9% | $-77.2M | $-68.9M | $-0.79 | — |
| Q4 2023 | $2.2M | 72.0% | $-66.7M | $-60.4M | $-0.79 | — |
| FY 2023 | $9.6M | 78.0% | $-235.6M | $-212.2M | $-2.91 | — |